Omicia Raises $6.8 Million to Accelerate Whole Genome Interpretation
News Jan 08, 2014
Other investors include Acadia Woods Partners, Bay City Capital, Buchanan Investments, and Casdin Capital.
“The support and significant oversubscription by these renowned firms and individuals will allow us to more rapidly execute our business plan to establish our healthcare IT platform, Opal, as the leader for analysis and interpretation of genomic data, whether for research or the clinic,” said Mike Aicher, Omicia’s CEO.
The pace of clinical genomics -- and personalized medicine in particular -- is accelerating and creating growing demand for fast, easy-to-use, but sophisticated analytical tools. “Clinical genomics is taking off, and we believe Opal offers substantial advantages over competitors,” said Stuart Peterson, president and founder of San Francisco-based Artis Ventures. “Top tier medical institutions are using the big data of next-generation sequencing to further distinguish themselves, and Opal is proving to be the optimal platform to achieve this.”
Omicia also announced today the appointment of two new members to its board of directors. Tad Buchanan, principal of Buchanan Investments, and William Gerber, MD, with Bay City Capital, will join Mike Aicher, CEO, John Stuelpnagel DVM, chairman and Martin Reese PhD, founder and president.
“These appointments further establish Omicia as the premiere company in genome analytics,” said Mike Aicher. “Tad and Bill are seasoned executives and investors who will play a pivotal role in ensuring we fulfill our strategic plan.”